Bioconjugation studies of an EGF-R targeting ligand on dendronized iron oxide nanoparticles to target head and neck cancer cells.

Fiche publication

Date publication

janvier 2023

Journal

International journal of pharmaceutics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BEGIN-COLIN Sylvie , Dr CHARBONNIERE Loïc , Dr MERTZ Damien

Tous les auteurs :
Freis B, De Los Ángeles Ramírez M, Furgiuele S, Journe F, Cheignon C, Charbonnière LJ, Henoumont C, Kiefer C, Mertz D, Affolter-Zbaraszczuk C, Meyer F, Saussez S, Laurent S, Tasso M, Bégin-Colin S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36720449

Résumé

A major challenge in nanomedicine is designing nanoplatforms (NPFs) to selectively target abnormal cells to ensure early diagnosis and targeted therapy. Among developed NPFs, iron oxide nanoparticles (IONPs) are good MRI contrast agents and can be used for therapy by hyperthermia and as radio-sensitizing agents. Active targeting is a promising method for selective IONPs accumulation in cancer tissues and is generally performed by using targeting ligands (TL). Here, a TL specific for the epidermal growth factor receptor (EGFR) is bound to the surface of dendronized IONPs to produce nanostructures able to specifically recognize EGFR-positive FaDu and 93-Vu head and neck cancer cell lines. Several parameters were optimized to ensure a high coupling yield and to adequately quantify the amount of TL per nanoparticle. Nanostructures with variable amounts of TL on the surface were produced and evaluated for their potential to specifically target and be thereafter internalized by cells. Compared to the bare NPs, the presence of the TL at the surface was shown to be effective to enhance their internalization and to play a role in the total amount of iron present per cell.